adult; advance care planning; aged; allogeneic stem cell transplantation; article; astrocyte; brain cancer; breast cancer; cancer chemotherapy; cancer immunotherapy; cancer incidence; cancer mortality; cancer screening; cancer staging; cancer survival; child; childhood cancer; clinical outcome; clinical practice; colorectal cancer; coronavirus disease 2019; counseling; drug efficacy; drug safety; endometrium cancer; estrogen receptor positive breast cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; event free survival; fatigue; female; female genital tract cancer; gastrointestinal cancer; germ cell tumor; glioblastoma; head and neck cancer; head and neck squamous cell carcinoma; health disparity; hemophagocytic syndrome; high throughput sequencing; hormonal therapy; hormone receptor-positive, HER2-negative breast cancer; human; intellectual impairment; liver cell carcinoma; lung cancer; lymphoproliferative disease; male; merkel cell carcinoma; meta analysis (topic); metastatic castration sensitive prostate cancer; neuroendocrine tumor; neutropenia; non small cell lung cancer; nutritional status; oncologist; ovary cancer; pancreas cancer; pharmacogenetic testing; phase 3 clinical trial (topic); physical activity; pleura mesothelioma; preoperative exercise; prevalence; prospective study; prostate cancer; quality of life; randomized controlled trial (topic); renal cell carcinoma; stomach adenocarcinoma; T lymphocyte; tertiary care center; transitional cell carcinoma; uterine cervix cancer; B Raf kinase; binimetinib/cb [Drug Combination]; binimetinib/cm [Drug Comparison]; circulating tumor DNA; docetaxel; dostarlimab; encorafenib/cb [Drug Combination]; encorafenib/cm [Drug Comparison]; fluoropyrimidine; glucuronosyltransferase 1A1; lenvatinib/cb [Drug Combination]; lenvatinib/cm [Drug Comparison]; palbociclib/cb [Drug Combination]; pembrolizumab/cb [Drug Combination]; pembrolizumab/cm [Drug Comparison]; placebo; programmed death 1 ligand 1; sitravatinib/cb [Drug Combination]; sunitinib/cm [Drug Comparison]; tepotinib; tislelizumab/cb [Drug Combination]; advanced renal cell carcinoma